Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors

被引:98
作者
Gómez-Ambrosi, J [1 ]
Salvador, J
Páramo, JA
Orbe, J
de Irala, J
Diez-Caballero, A
Gil, MJ
Cienfuegos, JA
Frühbeck, G
机构
[1] Univ Navarra Clin, Metab Res Lab, Pamplona, Spain
[2] Univ Navarra Clin, Dept Endocrinol, Pamplona, Spain
[3] Univ Navarra, Atherosclerosis Res Unit, Div Cardiovasc Pathophysiol & Biochem, E-31080 Pamplona, Spain
[4] Univ Navarra, Dept Epidemiol & Publ Hlth, E-31080 Pamplona, Spain
[5] Univ Navarra Clin, Dept Surg, Pamplona, Spain
[6] Univ Navarra Clin, Dept Biochem, Pamplona, Spain
关键词
obesity; cardiovascular risk; leptin; fibrinogen; insulin sensitivity;
D O I
10.1016/S0009-9120(02)00320-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Recent epidemiologic studies have shown that obesity is associated with elevated blood concentrations of prothrombotic-proinflammatory factors and markers of endothelial dysfunction such as fibrinogen, C-reactive protein (CRP), von Willebrand factor (vWF), and homocysteine. We have assessed whether these markers are associated with percentage of body fat (BF), insulin sensitivity as well as with leptin concentrations. Design and methods: Twenty-five men aged 49.6 +/- 12.7 yr (mean +/- SD) underwent whole-body air displacement plethysmography (Bod-Pod(R)) for estimating BF. Blood analyses for leptin and several other metabolic and cardiovascular markers were carried out. Results: Obese subjects had higher levels as compared to controls of BF (37.5 +/- 5.1 vs. 26.0 +/- 6.6, p < 0.01), fibrinogen (3.30 +/- 0.43 vs. 2.67 +/- 0.11, p < 0.01), vWF (136.4 +/- 50.4% vs. 81.6 +/- 12.6%, p < 0.05), and leptin (17.6 +/- 8.7 vs. 6.2 +/- 3.3, p < 0.01), lower concentrations of HDL-cholesterol (1.09 +/- 0.20 vs. 1.51 +/- 0.10, p < 0.001) and lower QUICKI (1/[Iog(Ins(0)) + log(Glu(0))]) (0.31 +/- 0.03 vs. 0.34 +/- 0.02, p < 0.05). No significant changes were observed in CRP (5.7 +/- 3.4 vs. 3.8 +/- 1.6, p = 0.327) and homocysteine (9.4 +/- 4.2 vs. 8.3 +/- 0.9, p = 0.749). A positive correlation was observed between BF and fibrinogen (r = 0.67, p = 0.0003). Plasma leptin concentrations were correlated with fibrinogen (r = 0.71, p = 0.0001) and CRP (r = 0.43, p = 0.044). After adjustment for BF leptin emerged as a significant predictor of fibrinogen (beta = 0.47, p = 0.023; R-2 = 0.59, p < 0.001). QUICKI was positively correlated with HDL-cholesterol (r = 0.59, p 0.010) and negatively with fibrinogen (r = -0.53, p 0.025), CRP (r = -0.52, p = 0.028) and vWF (r = -0.56, p = 0.013). Conclusions: Increased BF and impaired insulin sensitivity are associated with increased concentrations of cardiovascular risk factors. Leptin seems to be involved in this elevation and emerges as a predictor of circulating fibrinogen concentrations. (C) 2002 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:315 / 320
页数:6
相关论文
共 49 条
[1]  
Agata J, 1997, AM J HYPERTENS, V10, P1171
[2]   Association between obesity and coronary atherosclerosis and vascular remodeling [J].
Al Suwaidi, J ;
Higano, ST ;
Hamasaki, S ;
Holmes, DR ;
Lerman, A .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (11) :1300-+
[3]  
Bastard JP, 1999, CIRCULATION, V99, P2221
[4]  
Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898
[5]  
BLANN AD, 1993, INT J OBESITY, V17, P723
[6]  
Blann AD, 1997, AM J HEMATOL, V55, P15, DOI 10.1002/(SICI)1096-8652(199705)55:1<15::AID-AJH3>3.0.CO
[7]  
2-6
[8]   Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men [J].
Chu, NF ;
Spiegelman, D ;
Hotamisligil, GS ;
Rifai, N ;
Stampfer, M ;
Rimm, EB .
ATHEROSCLEROSIS, 2001, 157 (02) :495-503
[9]   Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men [J].
Cigolini, M ;
Targher, G ;
Andreis, IAB ;
Tonoli, M ;
Agostino, G ;
DeSandre, G .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (03) :368-374
[10]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237